|
original article |
Date |
Title |
Authors All Authors |
1 |
[GO] |
2024―Oct―07 |
NIH plots path forward for clinical trials of long COVID treatments |
Rowan Walrath |
2 |
[GO] |
2024―Sep―30 |
Competition finds potential coronavirus drugs |
Sarah Braner |
3 |
[GO] |
2024―Sep―30 |
R&D for long COVID is collapsing |
Rowan Walrath |
4 |
[GO] |
2024―Jul―01 |
Partnership is pandemic ready |
Aayushi Pratap |
5 |
[GO] |
2023―Nov―20 |
COVID Moonshot yields coronavirus antivirals |
Alla Katsnelson, special to C&EN |
6 |
[GO] |
2023―Oct―09 |
Gritstone advances COVID-19 vaccine |
Laura Howes |
7 |
[GO] |
2023―Sep―11 |
For long COVID, a growing understanding |
Shi En Kim |
8 |
[GO] |
2023―Apr―27 |
Sterling targets low-cost COVID-19 therapy |
Rick Mullin |
9 |
[GO] |
2023―Apr―27 |
FDA approves the Pfizer-BioNTech COVID-19 vaccine |
Megha Satyanarayana |
10 |
[GO] |
2023―Apr―27 |
COVID-19: What you need to know about SARS-CoV-2 variants |
Laura Howes |
11 |
[GO] |
2023―Apr―27 |
Over-the-counter COVID-19 tests make big promises. Do they deliver? |
Megha Satyanarayana |
12 |
[GO] |
2023―Apr―27 |
Pills to end the pandemic |
Bethany Halford |
13 |
[GO] |
2023―Apr―27 |
How ACS is emerging from COVID-19 restrictions and planning for the future |
Paul W. Jagodzinski, chair, ACS Board of Directors |
14 |
[GO] |
2023―Apr―27 |
AstraZeneca’s COVID-19 vaccine related woes grow |
Megha Satyanarayana |
15 |
[GO] |
2023―Apr―27 |
X-ray screening finds potential COVID-19 drugs |
Laura Howes |
16 |
[GO] |
2023―Apr―27 |
Merck to allow others to make COVID-19 pill |
Ryan Cross |
17 |
[GO] |
2023―Apr―27 |
How pregnancy affects COVID-19 vaccine response |
Laura Howes |
18 |
[GO] |
2023―Apr―27 |
EPA approves PPG’s COVID-19-killing paint |
Craig Bettenhausen |
19 |
[GO] |
2023―Apr―27 |
COVID-19 test used in UK mass-screening program receives rebuke from FDA |
Mark Peplow, special to C&EN |
20 |
[GO] |
2023―Apr―27 |
Keeping up with the coronavirus |
Laura Howes |
21 |
[GO] |
2023―Apr―27 |
Pfizer unveils its oral SARS-CoV-2 inhibitor |
Bethany Halford |
22 |
[GO] |
2023―Apr―26 |
COVID-19 clean is the new clean |
Craig Bettenhausen |
23 |
[GO] |
2023―Apr―26 |
Podcast: Jose-Luis Jimenez and Kimberly Prather on COVID-19 transmission and lessons for science communication |
Jyllian Kemsley |
24 |
[GO] |
2023―Apr―26 |
COVID-19 missteps revealed in 2021 |
Sam Lemonick |
25 |
[GO] |
2023―Apr―26 |
A strong and stable IP system incentivizes tools to combat COVID-19 |
Carlyn Burton, chair, ACS Committee on Patents and Related M |
26 |
[GO] |
2023―Apr―26 |
Women published less during early COVID-19 |
Andrea Widener |
27 |
[GO] |
2023―Apr―26 |
Atea’s COVID-19 drug fails in Phase 2 trials |
Megha Satyanarayana |
28 |
[GO] |
2023―Apr―26 |
mRNA COVID-19 vaccines by the numbers |
|
29 |
[GO] |
2023―Apr―26 |
Sanofi ditches mRNA vaccine for COVID-19 |
Ryan Cross |
30 |
[GO] |
2023―Apr―26 |
Merck drug blocks COVID-19 variants |
Megha Satyanarayana |
31 |
[GO] |
2023―Apr―26 |
Two COVID-19 antiviral pills advance to late-stage trials |
Megha Satyanarayana |
32 |
[GO] |
2023―Apr―26 |
The global mass of SARS-CoV-2 |
Laura Howes |
33 |
[GO] |
2023―Apr―26 |
4′-Fluorouridine fights SARS-CoV-2 in ferrets |
Bethany Halford |
34 |
[GO] |
2023―Apr―26 |
Looking at my ACS presidential year through the eyes of a pandemic |
Luis A Echegoyen, ACS immediate past president |
35 |
[GO] |
2023―Apr―25 |
To conquer COVID-19, create the perfect pill |
Bethany Halford |
36 |
[GO] |
2023―Apr―25 |
What computational scientists learned from COVID-19 |
Sam Lemonick |
37 |
[GO] |
2023―Apr―25 |
Air pollution disparities persisted during COVID-19 lockdowns |
Katherine Bourzac |
38 |
[GO] |
2023―Apr―25 |
CureVac stops work on COVID-19 vaccine |
Megha Satyanarayana |
39 |
[GO] |
2023―Apr―25 |
Sniffing out COVID-19 |
Carrie Arnold, special to C&EN |
40 |
[GO] |
2023―Apr―25 |
Third COVID-19 antibody is authorized |
Ryan Cross |
41 |
[GO] |
2023―Apr―25 |
Stopping COVID-19 where it starts |
Ryan Cross |
42 |
[GO] |
2023―Apr―25 |
Reemerging after COVID-19 |
Brought to you by ACS Careers |
43 |
[GO] |
2023―Apr―25 |
The antivirals that weren’t: Drug repurposing for COVID-19 produced misleading results |
Leigh Krietsch Boerner |
44 |
[GO] |
2023―Apr―25 |
Coronaviruses caused epidemics for millennia |
Laura Howes |
45 |
[GO] |
2023―Apr―25 |
Transistor detects SARS-CoV-2 in less than a minute |
Mark Peplow, special to C&EN |
46 |
[GO] |
2023―Apr―20 |
Pfizer to license COVID-19 antiviral |
Michael McCoy |
47 |
[GO] |
2023―Apr―19 |
Antibody drugs may prevent COVID-19 |
Megha Satyanarayana |
48 |
[GO] |
2022―Oct―17 |
Debate flares up on COVID-19 product IP |
Shi En Kim |
49 |
[GO] |
2022―Sep―12 |
The challenge of sustainable development in the era of COVID-19 |
Matt Fisher, Chair, ACS Committee on Science |
50 |
[GO] |
2022―Sep―12 |
China approves the first inhalable COVID-19 vaccine |
Shi En Kim |
51 |
[GO] |
2022―Sep―02 |
Moderna sues Pfizer and BioNTech over COVID-19 vaccine |
Gina Vitale |
52 |
[GO] |
2022―Jul―25 |
Paper strip detects SARS-CoV-2 variants |
Mark Peplow, special to C&EN |
53 |
[GO] |
2022―Jul―18 |
SARS-CoV-2’s survival in air depends on relative humidity |
Krystal Vasquez |
54 |
[GO] |
2022―Jun―06 |
Peptide from SARS-CoV-2 spike protein forms amyloids |
Celia Henry Arnaud |
55 |
[GO] |
2022―Mar―29 |
The next generation of COVID-19 antivirals |
Jared Whitlock, special to C&EN |
56 |
[GO] |
2022―Jan―31 |
Pittcon 2022 is canceled due to COVID-19 |
Craig Bettenhausen |
57 |
[GO] |
2021―Apr―05 |
Coffee pod COVID-19 test |
Laura Howes |
58 |
[GO] |
2021―Mar―29 |
AstraZeneca’s COVID-19 vaccine woes mount |
Ryan Cross |
59 |
[GO] |
2021―Mar―22 |
Women’s careers hurt more by COVID-19 pandemic than men’s |
Andrea Widener |
60 |
[GO] |
2021―Mar―22 |
Leprosy drug fights SARS-CoV-2 |
Bethany Halford |
61 |
[GO] |
2021―Mar―22 |
Petrochemicals to slump after the pandemic |
Alex Tullo |
62 |
[GO] |
2021―Mar―22 |
Undergrads hit hard by pandemic navigate disruptions |
Michele Solis, special to C&EN |
63 |
[GO] |
2021―Mar―15 |
FDA authorizes COVID-19 diagnostic that uses immune cells |
Megha Satyanarayana |
64 |
[GO] |
2021―Mar―15 |
Clearing the air of SARS-CoV-2 |
Mark Peplow, special to C&EN |
65 |
[GO] |
2021―Mar―15 |
CEPI has $3.5 billion plan to stop pandemics |
Ryan Cross |
66 |
[GO] |
2021―Mar―08 |
Pandemic emission reductions didn’t budge climate |
Katherine Bourzac |
67 |
[GO] |
2021―Mar―01 |
FDA outlines how to adapt COVID-19 vaccines to virus variants |
Asher Mullard, special to C&EN |
68 |
[GO] |
2021―Feb―22 |
Lipids for COVID-19 vaccines get investment |
Michael McCoy |
69 |
[GO] |
2021―Feb―02 |
Plitidepsin could fight COVID-19 |
Bethany Halford |
70 |
[GO] |
2021―Feb―02 |
Lilly antibody combo reduces COVID-19 deaths |
Megha Satyanarayana |
71 |
[GO] |
2021―Feb―02 |
What US chemists made before the COVID-19 pandemic |
Andrea Widener |
72 |
[GO] |
2021―Feb―02 |
How the pandemic changed the industrial chemistry workplace |
Chemjobber, special to C&EN |
73 |
[GO] |
2021―Jan―25 |
Surface swabbing could predict COVID-19 cases |
Mark Peplow, special to C&EN |
74 |
[GO] |
2021―Jan―25 |
How COVID-19 has changed the culture of science |
Bethany Halford |
75 |
[GO] |
2021―Jan―25 |
COVID-19: Science’s greatest test |
Lisa M. Jarvis |
76 |
[GO] |
2021―Jan―25 |
8 tools that helped us tackle the coronavirus |
Ryan Cross |
77 |
[GO] |
2021―Jan―25 |
Will public trust in science survive the pandemic? |
Ryan Cross |
78 |
[GO] |
2021―Jan―14 |
Pandemic stress: The toll it’s taking on students |
Wynne Parry, special to C&EN |
79 |
[GO] |
2021―Jan―04 |
US funds potential Merck COVID-19 drug |
Ryan Cross |
80 |
[GO] |
2021―Jan―04 |
Moderna’s COVID-19 vaccine to roll out across the US |
Ryan Cross |
81 |
[GO] |
2020―Dec―18 |
UK’s COVID-19 mass-screening program under fire |
Mark Peplow, special to C&EN |
82 |
[GO] |
2020―Dec―18 |
Pfizer COVID-19 vaccine rolls out across the US |
Ryan Cross |
83 |
[GO] |
2020―Dec―18 |
Coronavirus research dominated |
Laura Howes |
84 |
[GO] |
2020―Dec―09 |
The UK RECOVERY trial: An ambitious test of COVID-19 treatments |
Megha Satyanarayana |
85 |
[GO] |
2020―Dec―09 |
Biotech start-ups launched in spite of the pandemic |
Ryan Cross |
86 |
[GO] |
2020―Nov―30 |
A paint to kill COVID-19 |
Craig Bettenhausen |
87 |
[GO] |
2020―Nov―30 |
Merck makes third COVID-19 acquisition |
Megha Satyanarayana |
88 |
[GO] |
2020―Nov―30 |
Wacker to produce COVID-19 vaccine |
Alex Scott |
89 |
[GO] |
2020―Nov―23 |
Combined COVID-19 and flu tests could help overwhelmed hospitals |
Megha Satyanarayana |
90 |
[GO] |
2020―Nov―23 |
FDA grants EUA to at-home COVID-19 test |
Megha Satyanarayana |
91 |
[GO] |
2020―Nov―23 |
Moderna says COVID-19 vaccine is 94.5% effective in preliminary analysis |
Ryan Cross |
92 |
[GO] |
2020―Nov―23 |
CO2 could be bottleneck in COVID-19 vaccine rollout |
Craig Bettenhausen |
93 |
[GO] |
2020―Nov―23 |
Following SARS-CoV-2 down the drain |
Celia Henry Arnaud |
94 |
[GO] |
2020―Nov―23 |
SARS-CoV-2 envelope protein structure solved |
Laura Howes |
95 |
[GO] |
2020―Nov―23 |
Amid pandemic, chemical firms invest in R&D |
Michael McCoy |
96 |
[GO] |
2020―Nov―16 |
FDA authorizes COVID-19 antibody therapy |
Ryan Cross |
97 |
[GO] |
2020―Nov―16 |
Pfizer, BioNTech say their COVID-19 vaccine is successful in late-stage trial |
Ryan Cross |
98 |
[GO] |
2020―Nov―10 |
Roche taps Atea for COVID-19 antiviral |
Ryan Cross |
99 |
[GO] |
2020―Nov―02 |
Novartis gets access to COVID-19 therapies |
Michael McCoy |
100 |
[GO] |
2020―Oct―26 |
Tests alone won’t stop COVID-19 from spreading |
Megha Satyanarayana |
101 |
[GO] |
2020―Oct―26 |
New opportunities amid the challenges of the pandemic |
Lee H. Latimer, ACS director-at-large |
102 |
[GO] |
2020―Oct―26 |
Pandemic causes 6-month plunge in CO2 emissions |
Katherine Bourzac |
103 |
[GO] |
2020―Oct―19 |
Characterizing SARS-CoV-2 antibodies |
Laura Howes |
104 |
[GO] |
2020―Oct―19 |
How ACS student chapters are adapting to the pandemic |
Linda Wang |
105 |
[GO] |
2020―Oct―12 |
Small molecule takes aim at SARS-CoV-2 RNA |
Carolyn Wilke, special to C&EN |
106 |
[GO] |
2020―Oct―05 |
Understanding the COVID-19 bathroom risk |
Laura Howes |
107 |
[GO] |
2020―Oct―05 |
Biochemistry to boost garlic breath and an update to canine COVID-19 detection |
Laura Howes |
108 |
[GO] |
2020―Oct―05 |
The tiny tweak behind COVID-19 vaccines |
Ryan Cross |
109 |
[GO] |
2020―Sep―28 |
Pfizer tests COVID-19 antiviral |
Bethany Halford |
110 |
[GO] |
2020―Sep―28 |
COVID-19 lockdowns’ strange effects on air pollution |
Katherine Bourzac |
111 |
[GO] |
2020―Sep―28 |
Impact of COVID-19 on ACS finances |
William J. Greenlee |
112 |
[GO] |
2020―Sep―28 |
Coronavirus concerns dampen chemists’ economic outlook |
Andrea Widener |
113 |
[GO] |
2020―Sep―28 |
Glycans on SARS-CoV-2 may help the virus infect cells |
Alla Katsnelson, special to C&EN |
114 |
[GO] |
2020―Sep―21 |
Lilly antibody shows promise in COVID-19 |
Lisa M. Jarvis |
115 |
[GO] |
2020―Sep―21 |
Valneva wins UK contract for inactivated coronavirus vaccine |
Ryan Cross |
116 |
[GO] |
2020―Sep―14 |
Rise in quats observed during coronavirus crisis |
Laura Howes |
117 |
[GO] |
2020―Sep―08 |
15 min, $5 COVID-19 test rolls out |
Mark Peplow, special to C&EN |
118 |
[GO] |
2020―Sep―08 |
SARS-CoV-2 has stable genome |
Laura Howes |
119 |
[GO] |
2020―Aug―31 |
No link between blood type and COVID-19 |
Alla Katsnelson, special to C&EN |
120 |
[GO] |
2020―Aug―31 |
Saliva tests show promise for widespread COVID-19 surveillance at universities and workplaces |
Mark Peplow, special to C&EN |
121 |
[GO] |
2020―Aug―24 |
Flavor and fragrance firms dodge pandemic sales blow |
Michael McCoy |
122 |
[GO] |
2020―Aug―17 |
AI finds alternative routes to COVID-19 drug candidates |
Mark Peplow, special to C&EN |
123 |
[GO] |
2020―Aug―17 |
The rise of rapid COVID-19 testing |
Mark Peplow, special to C&EN |
124 |
[GO] |
2020―Aug―17 |
Coronavirus replication structure revealed |
Celia Henry Arnaud |
125 |
[GO] |
2020―Aug―03 |
CAS COVID-19 data set helps power PerkinElmer dashboard |
Linda Wang |
126 |
[GO] |
2020―Aug―03 |
First US Phase III trial of a COVID-19 vaccine begins |
Lisa M. Jarvis |
127 |
[GO] |
2020―Aug―03 |
Fujifilm signs two COVID-19 vaccine pacts |
Michael McCoy |
128 |
[GO] |
2020―Jul―28 |
Dow plans layoffs as COVID-19 bites earnings |
Alex Tullo |
129 |
[GO] |
2020―Jul―28 |
COVID-19 is more deadly to men. Probably. |
Leigh Krietsch Boerner |
130 |
[GO] |
2020―Jul―28 |
COVID-19 vaccines induce immune responses, but questions remain |
Ryan Cross |
131 |
[GO] |
2020―Jul―28 |
Stinkfrucht in Schweinfurt and sniffer dogs on the scent of SARS-CoV-2 |
Laura Howes |
132 |
[GO] |
2020―Jul―28 |
How SARS-CoV-2 stops cells producing protein |
Laura Howes |
133 |
[GO] |
2020―Jul―28 |
Starting a science business during a pandemic |
Craig Bettenhausen |
134 |
[GO] |
2020―Jul―20 |
Companies preview COVID-19 impact |
|
135 |
[GO] |
2020―Jul―20 |
What will it take to make an effective vaccine for COVID-19? |
|
136 |
[GO] |
2020―Jul―20 |
Adagio to make coronavirus antibodies |
|
137 |
[GO] |
2020―Jul―20 |
How ACS programs are adapting to the pandemic |
|
138 |
[GO] |
2020―Jul―20 |
Pandemic delays big US chemical projects |
|
139 |
[GO] |
2020―Jul―15 |
Developing nations face COVID-19 diagnostic challenges |
|
140 |
[GO] |
2020―Jul―15 |
US preorders COVID-19 vaccine and antibody therapy |
|
141 |
[GO] |
2020―Jul―06 |
Accuracy of COVID-19 antibody tests questioned |
|
142 |
[GO] |
2020―Jul―06 |
COVID-19 shakes up summer internships |
|
143 |
[GO] |
2020―Jul―06 |
FDA lays out COVID-19 vaccine requirements |
|
144 |
[GO] |
2020―Jul―06 |
Solar production is a pandemic bright spot |
|
145 |
[GO] |
2020―Jun―29 |
Doctors explore a popular heartburn drug for treating COVID-19 |
|
146 |
[GO] |
2020―Jun―29 |
Solvay warns of COVID-19 impact |
|
147 |
[GO] |
2020―Jun―29 |
Periodic Graphics: A guide to COVID-19 testing |
|
148 |
[GO] |
2020―Jun―29 |
COVID-19’s toll on environmental monitoring |
|
149 |
[GO] |
2020―Jun―29 |
Stranded by the pandemic |
|
150 |
[GO] |
2020―Jun―22 |
Dexamethasone could help in severe COVID-19 |
|
151 |
[GO] |
2020―Jun―22 |
COVID-19 vaccines and antibodies advance even faster than expected |
|
152 |
[GO] |
2020―Jun―22 |
Plastics during the pandemic |
|
153 |
[GO] |
2020―Jun―15 |
Blood type tied to COVID-19 risk |
|
154 |
[GO] |
2020―Jun―15 |
More COVID-19 vaccine manufacturing deals |
|
155 |
[GO] |
2020―Jun―08 |
Remembering the chemists we’ve lost to COVID-19 |
|
156 |
[GO] |
2020―Jun―08 |
COVID-19 antibody tests raise as many questions as they answer |
|
157 |
[GO] |
2020―Jun―08 |
COVID-19 antigen test becomes available in the US |
|
158 |
[GO] |
2020―Jun―08 |
COVID-19 forces cuts at Ingevity |
|
159 |
[GO] |
2020―Jun―08 |
Ginkgo gets cash for COVID-19 testing |
|
160 |
[GO] |
2020―Jun―08 |
Funds and deals fly for COVID-19 vaccine production |
|
161 |
[GO] |
2020―Jun―08 |
Lilly begins first clinical trial of antibody that targets SARS-CoV-2 |
|
162 |
[GO] |
2020―Jun―08 |
Pandemic puts preprints first |
|
163 |
[GO] |
2020―Jun―01 |
Artemisinin raises hopes and fears amid COVID-19 |
|
164 |
[GO] |
2020―Jun―01 |
Business cards in the time of COVID-19 |
|
165 |
[GO] |
2020―Jun―01 |
First COVID-19 vaccine data is out |
|
166 |
[GO] |
2020―Jun―01 |
Merck & Co. joins race for COVID-19 vaccines and therapies |
|
167 |
[GO] |
2020―May―25 |
Rethinking the role of blood pressure drugs in COVID-19 |
|
168 |
[GO] |
2020―May―25 |
An emerging antiviral takes aim at COVID-19 |
|
169 |
[GO] |
2020―May―25 |
Sumitomo funds COVID-19 detector |
|
170 |
[GO] |
2020―May―25 |
US signs huge COVID-19 drug contract with a start-up |
|
171 |
[GO] |
2020―May―25 |
How COVID-19 has put accessibility front and center |
|
172 |
[GO] |
2020―May―25 |
COVID-19 pushes firms to close plants, cut projects |
|
173 |
[GO] |
2020―May―25 |
Partners seek CRISPR COVID-19 test |
|
174 |
[GO] |
2020―May―25 |
US backs UK COVID-19 vaccine |
|
175 |
[GO] |
2020―May―25 |
Moderna provides cursory glance at first COVID-19 vaccine data |
|
176 |
[GO] |
2020―May―25 |
Can NO treat COVID-19? |
|
177 |
[GO] |
2020―May―25 |
CDC sidelined in coronavirus briefings |
|
178 |
[GO] |
2020―May―25 |
CO2 emissions drop by 17% during the pandemic |
|
179 |
[GO] |
2020―May―18 |
Coatings and COVID-19 |
|
180 |
[GO] |
2020―May―18 |
Getting back to the lab during COVID-19 |
|
181 |
[GO] |
2020―May―18 |
Drug, chemical firms open COVID-19 patents |
|
182 |
[GO] |
2020―May―18 |
CEPI commits $384 million to Novavax’s COVID-19 vaccine |
|
183 |
[GO] |
2020―May―18 |
Can adenoviral vectors overcome a checkered past to win the COVID-19 vaccine race? |
|
184 |
[GO] |
2020―May―18 |
COVID-19’s CO2 impact |
|
185 |
[GO] |
2020―May―18 |
Faculty open up about mental health under a pandemic |
|
186 |
[GO] |
2020―May―11 |
Modelers pledge openness to combat COVID-19 |
|
187 |
[GO] |
2020―May―11 |
FDA adjusts course on validating COVID-19 antibody tests |
|
188 |
[GO] |
2020―May―11 |
ACC seeks lower tariffs to aid COVID-19 fight |
|
189 |
[GO] |
2020―May―11 |
AAV-based COVID-19 vaccine is planned |
|
190 |
[GO] |
2020―May―11 |
STEM-ucation in the time of the coronavirus |
|
191 |
[GO] |
2020―May―11 |
Big pharma’s quiet effort to find new coronavirus antivirals |
|
192 |
[GO] |
2020―May―11 |
Navigating the coronavirus job crisis |
|
193 |
[GO] |
2020―May―11 |
Lonza to make Moderna coronavirus vaccine |
|
194 |
[GO] |
2020―May―11 |
How remdesivir blocks SARS-CoV-2 |
|
195 |
[GO] |
2020―May―11 |
Cell studies follow up on previous SARS-CoV-2 studyCell studies follow up on previous SARS-CoV-2 study |
|
196 |
[GO] |
2020―May―11 |
Pandemic hits chemical earnings |
|
197 |
[GO] |
2020―May―04 |
Genomic epidemiology put to the test against COVID-19 |
|
198 |
[GO] |
2020―May―04 |
IL-6 antibody shows no COVID-19 benefit |
|
199 |
[GO] |
2020―May―04 |
J&J picks partners for COVID-19 vaccine |
|
200 |
[GO] |
2020―May―04 |
Podcast: Beating a killer coronavirus |
|
201 |
[GO] |
2020―May―04 |
Scaling up remdesivir amid the coronavirus crisis |
|
202 |
[GO] |
2020―May―04 |
Coronavirus entry points could explain its spread |
|
203 |
[GO] |
2020―May―04 |
The race to reveal the new coronavirus’s structure |
|
204 |
[GO] |
2020―Apr―27 |
Lending a machine to combat COVID-19 |
|
205 |
[GO] |
2020―Apr―27 |
Antimalarial drugs put to the test for COVID-19 |
|
206 |
[GO] |
2020―Apr―27 |
Ease COVID-19 border controls, say EU CEOs |
|
207 |
[GO] |
2020―Apr―27 |
NIH consortium to tackle COVID-19 research |
|
208 |
[GO] |
2020―Apr―27 |
Adding the missing sugars to coronavirus protein structures |
|
209 |
[GO] |
2020―Apr―20 |
Lilly to test baricitinib against COVID-19 |
|
210 |
[GO] |
2020―Apr―20 |
Computers against COVID-19 |
|
211 |
[GO] |
2020―Apr―20 |
COVID-19 puts damper on chemical deals |
|
212 |
[GO] |
2020―Apr―20 |
Fujifilm tests favipiravir as COVID-19 treatment |
|
213 |
[GO] |
2020―Apr―20 |
Merck KGaA helps scale COVID-19 vaccine |
|
214 |
[GO] |
2020―Apr―20 |
COVID-19 vaccines move toward clinic |
|
215 |
[GO] |
2020―Apr―20 |
Vir taps Samsung for coronavirus candidate |
|
216 |
[GO] |
2020―Apr―20 |
Another coronavirus drug target imaged |
|
217 |
[GO] |
2020―Apr―20 |
Novel coronavirus found in sewage |
|
218 |
[GO] |
2020―Apr―20 |
What we know about the novel coronavirus’s proteins |
|
219 |
[GO] |
2020―Apr―20 |
How susceptible is your pet to the novel coronavirus? |
|
220 |
[GO] |
2020―Apr―20 |
Yeasty treats to get you through the pandemic |
|
221 |
[GO] |
2020―Apr―13 |
Ruxolitinib to be tested in fight against COVID-19 |
|
222 |
[GO] |
2020―Apr―13 |
Carbon rolls out 3-D printing for COVID-19 |
|
223 |
[GO] |
2020―Apr―13 |
States roll back bag bans for COVID-19 |
|
224 |
[GO] |
2020―Apr―13 |
Nova slows projects because of COVID-19 |
|
225 |
[GO] |
2020―Apr―13 |
Amgen pursues COVID-19 antibodies |
|
226 |
[GO] |
2020―Apr―13 |
GSK strikes COVID-19 partnerships |
|
227 |
[GO] |
2020―Apr―13 |
Companies are racing to develop COVID-19 tests for the US. Will the tests help? |
|
228 |
[GO] |
2020―Apr―13 |
Searching for a coronavirus cure in the blood |
|
229 |
[GO] |
2020―Apr―13 |
Will the coronavirus help mRNA and DNA vaccines prove their worth? |
|
230 |
[GO] |
2020―Apr―13 |
How a SARS antibody binds to SARS-CoV-2 |
|
231 |
[GO] |
2020―Apr―06 |
Reagents hold up European COVID-19 tests |
|
232 |
[GO] |
2020―Apr―06 |
COVID-19 to delay clinical trials |
|
233 |
[GO] |
2020―Apr―06 |
Grad students on COVID-19’s impact |
|
234 |
[GO] |
2020―Apr―06 |
What could remdesivir data tell us about tackling COVID-19? |
|
235 |
[GO] |
2020―Apr―06 |
How ACS is adapting to the coronavirus pandemic |
|
236 |
[GO] |
2020―Apr―06 |
Faculty cope with coronavirus shutdowns |
|
237 |
[GO] |
2020―Apr―06 |
Coronavirus starts to weigh on industry |
|
238 |
[GO] |
2020―Apr―06 |
J&J, BARDA advance coronavirus vaccine |
|
239 |
[GO] |
2020―Apr―06 |
Did pangolins help spread SARS-CoV-2? |
|
240 |
[GO] |
2020―Apr―03 |
Emory drug licensed for COVID-19 |
|
241 |
[GO] |
2020―Apr―03 |
Protein mapping points to 69 potential COVID-19 treatments |
|
242 |
[GO] |
2020―Apr―03 |
Tips for teaching in the time of the coronavirus |
|
243 |
[GO] |
2020―Apr―03 |
Material shortages hamper testing for novel coronavirus |
|
244 |
[GO] |
2020―Apr―03 |
T-cell therapies aimed at novel coronavirus |
|
245 |
[GO] |
2020―Apr―03 |
3-D printing firms rise to coronavirus challenge |
|
246 |
[GO] |
2020―Apr―03 |
US government allows funding flexibility during coronavirus outbreak |
|
247 |
[GO] |
2020―Apr―03 |
Targeting a coronavirus protease |
|
248 |
[GO] |
2020―Apr―03 |
Coronavirus puts spotlight on chloroquine |
|
249 |
[GO] |
2020―Apr―03 |
Professional training in the time of a pandemic |
|
250 |
[GO] |
2020―Mar―23 |
IL-6 blockers tested against COVID-19 |
|
251 |
[GO] |
2020―Mar―23 |
How we know disinfectants should kill the COVID-19 coronavirus |
|
252 |
[GO] |
2020―Mar―23 |
COVID-19 coronavirus weighs on economy, chemicals |
|
253 |
[GO] |
2020―Mar―23 |
Chemistry departments deal with coronavirus closures |
|
254 |
[GO] |
2020―Mar―23 |
BioNTech joins the coronavirus vaccine race |
|
255 |
[GO] |
2020―Mar―16 |
US allocates $8.3 billion for coronavirus |
|
256 |
[GO] |
2020―Mar―16 |
Chemistry in the time of the coronavirus |
|
257 |
[GO] |
2020―Mar―16 |
Coronavirus hits Europe |
|
258 |
[GO] |
2020―Mar―16 |
Another novel coronavirus structure solved |
|
259 |
[GO] |
2020―Mar―16 |
Heavy hitters join for coronavirus treatments |
|
260 |
[GO] |
2020―Mar―09 |
Pittcon goes ahead despite coronavirus |
|
261 |
[GO] |
2020―Mar―09 |
Coronavirus cancels chemical events |
|
262 |
[GO] |
2020―Mar―09 |
CDC’s coronavirus test runs into early problems |
|
263 |
[GO] |
2020―Mar―09 |
Gilead and Moderna lead on coronavirus treatments |
|
264 |
[GO] |
2020―Feb―24 |
Diagnosing COVID-19 |
|
265 |
[GO] |
2020―Feb―24 |
Sanofi, BARDA team for coronavirus vaccine |
|
266 |
[GO] |
2020―Feb―24 |
Structure of novel coronavirus’s spike protein solved |
|
267 |
[GO] |
2020―Feb―17 |
Biotech start-ups hit by coronavirus work stoppages |
|
268 |
[GO] |
2020―Feb―10 |
Artificial intelligence finds drugs that could fight the new coronavirus |
|
269 |
[GO] |
2020―Feb―10 |
China’s chemical industry shadowed by the coronavirus |
|
270 |
[GO] |
2020―Feb―10 |
Coronavirus puts drug chemical industry on alert |
|
271 |
[GO] |
2020―Feb―10 |
GSK and CEPI partner on coronavirus vaccine |
|
272 |
[GO] |
2020―Feb―03 |
Pharma mobilizes to combat the coronavirus |
|